AZN

AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

AstraZeneca PLC is a high-quality compounder leveraging mid-single-digit revenue growth into robust EPS gains, driven by oncology and pipeline execution. Recent EU approval of Trixeo Aerosphere for asthma expands AZN's addressable market, reinforcing its Respiratory & Immunology franchise with durable, long-cycle growth potential. AZN's pipeline momentum—six positive Phase III readouts and 30 approvals—underpins its long-term growth narrative despite isolated late-stage failures.

The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have declined cisplatin-based chemotherapy. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer signific.

IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.

AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx, a leading provider of long-term care, specialty, and infusion pharmacy solutions, has once again been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service, available for the 2026-2027 flu season. This marks the second consecutive year Polaris Rx has earned this exclusive distinction. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home without a doc.

In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.

AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.